Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Disintegrins and disintegrin-like proteins are a family of small, cysteine-rich polypeptides found in the venoms of vipers and rattlesnakes, including Bothrops asper and Crotalus durissus (UniProt, Family: Disintegrin). These molecules function as potent antagonists of integrin receptors, particularly the platelet receptor αIIbβ3 and various αv integrins on endothelial cells (McLane et al., 2004, Frontiers in Bioscience). By mimicking the Arg-Gly-Asp (RGD) recognition sequence, they competitively inhibit the binding of adhesive glycoproteins like fibrinogen, leading to the suppression of platelet aggregation and cell-matrix interactions (Calvete et al., 2005, Venom Genomics and Proteomics). This activity is a primary driver of the hemorrhagic effects observed during snakebite envenomation, as it disrupts normal blood clotting and vascular stability (WHO Guidelines for Snake Antivenoms). While they are pathological in the context of a snakebite, their high specificity for integrins has made them invaluable templates for the development of clinical antiplatelet drugs such as eptifibatide and tirofiban. In clinical toxicology, these toxins are the specific targets for neutralization by polyvalent antivenoms, which contain antibodies that bind the toxins and prevent their interaction with host receptors. Research also explores their potential as anti-angiogenic and anti-metastatic agents in cancer therapy due to their ability to block integrin-mediated cell signaling. Despite their therapeutic utility as lead compounds, the native toxins pose significant safety risks, including severe systemic bleeding and potential immunogenicity if used directly as therapeutics.
Neutralization of toxin activity through antibody-mediated sequestration, which prevents the toxin from interacting with host integrin receptors such as αIIbβ3 and αvβ3 (WHO Guidelines for Snake Antivenoms).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Snake venom disintegrin.